1536470-92-4
1536470-92-4
Chemical Structure
SML-8-73-1
- CAS No.: 1536470-92-4
- Formula:C14H21ClN6O12P2
- Molecular Weight:562.75
InChIKey: LYRLHTRLCKSXIV-ZRFIDHNTSA-N
SMILES: O=C1C(N=CN2[C@@H]3O[C@H](COP(OP(OCCNC(CCl)=O)(O)=O)(O)=O)[C@@H](O)[C@H]3O)=C2N=C(N)N1
Biological Activity: SML-8-73-1 is a nucleotide-based KRASG12C inhibitor. SML-8-73-1 can be used for the study of non-small cell lung cancer (NSCLC)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SML-8-73-1 | SML-8-73-1 is a nucleotide-based KRASG12C inhibitor. SML-8-73-1 can be used for the study of non-small cell lung cancer (NSCLC). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lim SM, et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl. 2014 Jan 3;53(1):199-204. [Content Brief]
- [2]. Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. [Content Brief]
Keywords
